Phenotyping at scale across diverse biobank cohorts to power genomic & proteomic analyses for target identification, drug discovery, and precision medicine.
Contributing clinical experience, data wrangling and analytical skills to development of COVID-19 Severity phenotypes from linked EHR data for 54 million patients in England.